LEP and metabolic dysfunction-associated steatotic liver disease: Patients with lipodystrophy are treated with leptin recombinant treatments, such as metreleptin, approved by the United States Food and Drug Administration (FDA) and the Japanese Pharmaceuticals and Medical Devices Agency, since it improves many associated metabolic disorders such as insulin sensitivity, glucose tolerance, hypertriglyceridemia or NAFLD [59,60,61].